Screening strategies and predictive diagnostic tools for the development of new-onset diabetes mellitus after transplantation: an overview by Pham PT et al.
© 2012 Pham et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article  
which permits unrestricted noncommercial use, provided the original work is properly cited.
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy 2012:5 379–387
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Screening strategies and predictive diagnostic 
tools for the development of new-onset diabetes 
mellitus after transplantation: an overview
Phuong-Thu T Pham1
Kari L Edling2
Harini A Chakkera3
Phuong-Chi T Pham4
Phuong-Mai T Pham5
1Department of Medicine, Nephrology 
Division, Kidney Transplant Program, 
David Geffen School of Medicine 
at UCLA, Los Angeles, CA, USA; 
2Department of Medicine, Division 
of Endocrinology, Diabetes and 
Hypertension, David Geffen 
School of Medicine at UCLA, Los 
Angeles, CA, USA; 3Department 
of Medicine, Nephrology Division 
Kidney Transplant Program, Mayo 
Clinic Hospital, Phoenix, AZ, USA; 
4Department of Medicine, Nephrology 
Division, UCLA-Olive View Medical 
Center, Sylmar, CA, USA; 5Department 
of Medicine, Greater Los Angeles, 
Veterans Administration Health Care 
System, CA, USA
Correspondence: Phuong-Thu T Pham 
Department of Medicine, Nephrology 
Division, Kidney Transplant Program, 
David Geffen School of Medicine at 
UCLA, Los Angeles, CA 90095, USA 
Tel +1 310 794 1757 
Fax +1 310 825 6309 
Email PPham@mednet.ucla.edu
Abstract: New-onset diabetes mellitus after transplantation (NODAT) is a serious and common 
complication following solid organ transplantation. NODAT has been reported in 2% to 53% 
of all solid organ transplants. Kidney transplant recipients who develop NODAT have vari-
ably been reported to be at increased risk of fatal and nonfatal cardiovascular events and other 
adverse outcomes including infection, reduced patient survival, graft rejection, and accelerated 
graft loss compared with those who do not develop diabetes. Limited clinical studies in liver, 
heart, and lung transplants similarly suggested that NODAT has an adverse impact on patient 
and graft outcomes. Early detection and management of NODAT must, therefore, be integrated 
into the treatment of transplant recipients. Studies investigating the best screening or predictive 
tool for identifying patients at risk for developing NODAT early after transplantation, however, 
are lacking. We review the clinical predictive values of fasting plasma glucose, oral glucose 
tolerance test, and A1C in assessing the risk for NODAT development and as a screening tool. 
Simple diabetes prediction models that incorporate clinical and/or metabolic risk factors (such 
as age, body mass index, hypertriglyceridemia, or metabolic syndrome) are also presented.
Keywords: new-onset diabetes after transplantation, impaired fasting glucose, impaired glucose 
tolerance, oral glucose tolerance test, NODAT screening, diabetes prediction models
Introduction
The development of diabetes mellitus after kidney transplantation attributed to steroid 
use was first reported by Starlz in 1964,1 and subsequently recognized as a complication 
of kidney transplantation in the 1970s. New-onset diabetes after solid organ transplanta-
tion associated with the use of immunosuppressive therapy (eg, steroids, cyclosporine, 
tacrolimus, sirolimus, and everolimus) has now been well described. Over the years, 
it has undergone changes in nomenclatures including steroid diabetes, posttransplant 
diabetes mellitus, new-onset diabetes mellitus, transplant-associated hyperglycemia, 
and most recently, new-onset diabetes after transplantation (NODAT). NODAT is a 
complex metabolic disorder characterized by a relative or absolute impairment in insu-
lin secretion, along with varying degrees of peripheral insulin resistance. In essence, 
NODAT resembles type 2 diabetes and the diagnosis may be delayed or unrecognized. 
Indeed, over the years, the precise incidence of NODAT has been difficult to determine 
due to the lack of standard criteria defined for the condition. In 2003, the International 
Expert Panel consisting of experts from both the transplant and diabetes fields set 
forth the International Consensus Guidelines for the diagnosis and management of 
NODAT.2,3 It was recommended that the definition and diagnosis of NODAT be based 
on the definition of diabetes mellitus and impaired glucose tolerance (IGT) described 
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by the World Health Organization (WHO).3,4 It is notewor-
thy that while the 2003 International Consensus Guidelines 
defined normal fasting plasma glucose (FPG) as a plasma 
glucose of ,110 mg/dL (6.1 mmol/L), the 2003 American 
Diabetes Association (ADA) expert committee had lowered 
the diagnostic threshold for impaired FPG to $100 mg/dL 
(5.6 mmol/L). The 2010 updated ADA consensus report 
included an A1C level of $6.5% as an alternative diagnos-
tic criterion for diabetes mellitus in the general population 
based on the observed association between A1C level and 
the risk for future development of retinopathy. The current 
WHO and ADA guidelines for the diagnosis of prediabetic 
states (impaired fasting glucose [IFG] and IGT) and diabetes 
mellitus are provided in Table 1.
Studies in the general population have demonstrated that 
individuals with IFG, IGT, and/or an A1C value between 
5.7% to 6.4% are at increased risk for future development 
of diabetes. Similar to the nontransplant settings, impaired 
glucose metabolism in the pre- and/or posttransplant period 
has been suggested to be a predictive risk factor for the devel-
opment of NODAT. However, studies investigating the best 
screening or predictive tool for identifying patients at risk for 
developing NODAT early after transplantation are lacking. 
In this article, an overview of the literature on the utilization 
of currently available glycemic tests to predict or detect sub-
clinical NODAT are discussed. Simple diabetes-prediction 
models that incorporate clinical and/or laboratory risk factors 
are also presented, followed by the authors’ perspective on 
the utility of various glycemic tests and diabetes-prediction 
models in the screening and diagnosis of NODAT.
Literature overview on the utility 
of FPG,   A1C, and/or an oral glucose 
tolerance test
The utility of FPG and OGTT in the 
prediction of NODAT development  
and as a screening tool
Glycemic testing in the early posttransplant  
period (fifth posttransplant day)
Kuypers et al4 evaluated the utility of determining FPG levels 
and performing an oral glucose tolerance test (OGTT) in the 
early posttransplantation period for the prediction of NODAT 
development. The 2003 ADA criteria were used to define 
IGT, IFG, and diabetes mellitus. NODAT was defined as the 
uninterrupted need for glucose-lowering therapy for at least 
3 months following transplantation. Renal allograft recipients 
with pre-existing diabetes mellitus were excluded from the 
study. All patients in the study completed an OGTT 5 days 
after transplantation, as stipulated by the WHO. In total, 359 
eligible de novo renal transplant recipients were enrolled in 
the study. At a mean follow-up of 42.8 ± 16.9 months, 64 
patients (17.8%) had developed NODAT. A normal (vs dia-
betic) OGTT at 5 days after transplantation was associated 
with a reduced risk of NODAT (odds ratio, 0.03; P = 0.0002). 
A similar risk reduction was conferred by a normal (vs 
diabetic) FPG level on day 5 (odds ratio, 0.06; P # 0.0001). 
The OGTT on day 5 had better sensitivity (93.4% vs 21.6%) 
and a higher negative predictive value (97.6% vs 89.1%) than 
FPG test on day 5, but poorer specificity (71.9% vs 97.6%) 
and a lower positive predictive value (47.2% vs 61.5%). 
For transplant recipients who developed NODAT very early 
following transplantation, the concern arose that the OGTT 
on day 5 served merely as a diagnostic rather than a predictive 
Table 1 wHO and ADA criteria for the diagnosis of diabetes 
mellitus
Criteria for the diagnosis of DM
Any one of the following:
1.    Classic symptoms of DMa + random PG concentrations $ 200 mg/dL 
(11.1 mM)
2.    FPG $126 mg/dL (7.0 mM). Fasting is defined as no caloric intake  
for $8 hours
3.  2-hour PG $ 200 mg/dL (11.1 mM) during an OGTTb
4.  A1Cc $ 6.5%
in the absence of unequivocal hyperglycemia accompanied by acute 
metabolic decompensation, criteria 2–4 must be confirmed by repeat 
testing on another day.
Criteria for normal FPG and IFG or IGT
•  FPG
    WHO criteria
    FPG , 110 mg/dL (6.1 mM) = normal fasting glucose
    FPG $ 110 mg/dL (6.1 mM) and ,126 mg/dL (7.0 mM) = iFG
    2003 ADA consensus
    FPG , 100 mg/dL (5.6 mM) = normal fasting glucose
    FPG $ 100 mg/dL (5.6 mM) and ,126 mg/dL (7.0 mM) = iFG
OR
•  OGTT
    2-hour PG , 140 mg/dL (7.8 mM) = normal glucose tolerance
    2-hour PG $ 140 mg/dL (7.8 mM) and , 200 mg/dl (11.1 nM) = iGT
Prediabetic states based on A1C level
2010 ADA consensus: 5.7%–6.4%
International expert committee: 6.0%–6.4%
Notes:  aClassic  symptoms  of  DM  include  polyuria,  polydipsia,  and  unexplained 
weight loss; bOGTT: the test should be performed as described by wHO, using a 
glucose load containing equivalent of 75 g anhydrous glucose dissolved in water; cA1C 
should be performed using a method certified by the National Glycohemoglobin 
Standardization Program (NGSP) and standardized to the Diabetes Control and 
Complications Trial (DCCT) reference assay.
Abbreviations:  wHO,  world  Health  Organization;  ADA,  American  Diabetes 
Association; DM, diabetes mellitus; PG, plasma glucose; FPG, fasting plasma glucose; 
iFG, impaired fasting glucose; iGT, impaired glucose tolerance; OGTT, oral glucose 
tolerance test.
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tool. However, a multivariate analysis involving only those 
who developed NODAT 2 or more weeks after the OGTT 
revealed a similarly significant association between a normal 
OGTT and a reduced risk for “delayed” NODAT. The results 
of the study suggested that a normal FPG (vs diabetic) and 
a normal OGTT (vs diabetic) at 5 days after transplantation 
seem to identify recipients at reduced risk for NODAT, at 
least among white subjects (91.4% of the study population 
were white, 1.4% were black, and Hispanics were absent). 
These findings remain to be validated in patients of other 
ethnicities.5
A Spanish study by Rodrigo et al6 also examined the 
predictive value of a fifth-day posttransplantation FPG. 
Of 282 previously nondiabetic patients, 46 (16.3%) 
developed NODAT by the 1-year follow-up. A fifth day 
FPG $ 126 mg/dL was associated with a more than fourfold 
increase in NODAT risk (relative risk, 4.784; 95% confidence 
interval [CI]: 2.121–10.788; P = 0.002). The positive and 
negative predictive value of a fifth day FPG $ 126 mg/dL 
for predicting NODAT at 1-year were 40% and 89.4%, 
respectively. The negative predictive value of nearly 90% 
suggested that a nondiabetic FPG may identify patients who 
are at lower risk for developing NODAT and therefore require 
less intensive screening in the future.
Glycemic testing after the first 6 months 
posttransplantation
Armstrong et al7 were among the first to examine the predictive 
power of FPG with respect to 2-hour blood glucose. A total 
of 200 previously nondiabetic renal transplant recipients who 
were more than 6 months posttransplantation underwent a 
standard 2-hour OGTT. Patients with FPG , 126 mg/dL 
(7.0 mmol/L; n = 188) underwent an OGTT. Receiver-
operating characteristics (ROC) analyses were used to 
evaluate the optimal level of FPG that was predictive of 
NODAT (2-hour blood glucose $ 200 mg/dL; 11.0 mmol/L) 
and IGT (2-hour blood glucose of 140–200 mg/dL or 
7.8–11.0 mmol/L). Forty-two percent of study subjects 
were found to have an abnormal OGTT (NODAT in 12% 
and IGT in 30%). The optimal FPG that was predictive 
of NODAT was 101 mg/dL (5.6 mmol/L; area under the 
curve, 0.70; sensitivity, 64%; specificity, 67%; positive 
predictive value, 20%; negative predictive value, 93%). 
The optimal FPG that was predictive of IGT was less well 
defined (area under the curve, 0.54). The prevalence of 
NODAT was higher by OGTT than by FPG alone (17% vs 
6%; P , 0.0001). However, it is noteworthy that more than 
80% of the study population was white. Inclusion of more 
patients with diverse ethnic background might have altered 
the reported prevalence of NODAT and IGT. Nonetheless, 
results from the study suggested that FPG may not be the 
optimal screening or diagnostic tool for NODAT or IGT due 
to its lack of sensitivity and specificity. Hence, the authors 
proposed that OGTT should be considered as a routine 
screening test in all renal transplant recipients.
In a prospective study designed to evaluate the value of 
OGTT for risk-stratifying patients for NODAT, Sharif et al8 
demonstrated that among 122 renal transplant recipients 
without diabetes who had two FPG level measurements 
within the range of 100–125 mg/dL (5.6–6.9 mmol/L) more 
than 6 months after transplantation, OGTT revealed that 
10% had overt diabetes mellitus, 9% had IGT alone, 18% 
had IFG alone (all defined by WHO criteria), and 14% had 
combined IFG and IGT. In agreement with most studies, this 
study demonstrated that FPG underestimates the prevalence 
of NODAT and IGT and suggested the routine use of OGTT 
in risk stratifying renal transplant recipients for the develop-
ment of NODAT.
The utility of FPG and A1C in the 
prediction of NODAT development  
and as a screening tool
Hoban et al9 first described the utility of A1C in the 
detection of subclinical NODAT in recipients of kidney 
transplant recipients. The study consisted of 199 previ-
ously nondiabetic adult kidney transplant recipients who 
were $3 months posttransplant (one subject was enrolled 
at 73 days posttransplant). All study subjects were required 
to have a history of normal FPG (not defined) prior to study 
entry. Pregnant patients, patients on dialysis and those with 
recent blood transfusion or blood loss that might affect A1C 
measurements were excluded. A normal A1C was defined 
as an A1C of ,6.1%. Of 199 patients studied, 20 (10.1%) 
were found to have an A1C $ 6.1%, six of whom had both 
elevated A1C and new-onset elevated FPG at study entry 
despite a history of normoglycemia. In clinical follow-up 
(6.9 years posttransplant), 13 of the 20 (all six patients with 
both elevated FPG and A1C) and seven of the 14 patients 
with only elevated A1C had medical intervention for 
diabetes or glucose intolerance. Of the six patients with 
elevated A1C and FPG, five were eventually diagnosed with 
diabetes mellitus at long-term follow-up. Of the 14 patients 
with elevated A1C and normal screening FPG, three were 
diagnosed with diabetes mellitus and four with glucose 
intolerance. Notably, the odds of African Americans having 
an elevated A1C were 2.8 times higher than those of other 
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races, with 19.4% of African Americans having elevated 
A1C compared with 8% of their non-African American 
counterparts. However, multivariate logistic regression 
analysis demonstrated that high normal FPG was signifi-
cantly associated with an elevated A1C (P = 0.003), whereas 
an ethnicity effect was only marginally significant when 
adjusted for FPG (P = 0.08). The investigators concluded 
that A1C level was a more sensitive test than FPG in detect-
ing NODAT and further validated this recommendation 
in African Americans. Nonetheless, their study was not 
without shortcomings. The rationale for using an A1C level 
of $6.1% to screen for NODAT was not defined and the 
number of patients undergoing the gold standard OGTT was 
not stated. Furthermore, African Americans predominated 
the study population (81.9%). Hence, the use of A1C as a 
screening or diagnostic tool in the setting of organ trans-
plantation has yet to be validated.
The utility of FPG and A1C in the 
selection of patients to undergo OGTT
In a single center study, Valderhaug et al10 aimed to assess 
the accuracy of FPG and A1C for the selection of patients 
who should undergo a diagnostic OGTT 10 weeks after renal 
transplantation. Among the 1637 previously nondiabetic renal 
transplant recipients who were prospectively examined 10 
weeks after transplantation, 66 patients were found to have 
manifest NODAT and were excluded from oral glucose toler-
ance testing. The remaining 1571 patients with   previously 
normal FPG underwent an OGTT. Of these, 213 (14%) 
were diagnosed with NODAT, 51% of whom (n = 109) were 
identified by 2-hour PG $ 11.1 mmol/L alone, and 17% 
(n = 35) by FPG alone (FPG $ 7.0 mmol/L). Sixty-nine 
patients (32%) fulfilled both criteria for NODAT. To assess 
the diagnostic accuracy of FPG and A1C to predict a 2-hour 
PG . 11.1 mmol/L, an analysis involving a subgroup of 
patients with a FPG of ,7 mmol/L and available A1C levels 
(n = 929) was performed. Receiver operating characteristic 
analysis revealed an area under the curve of 0.761 (95% 
confidence interval [CI]: 0.714–0.809) for FPG and 0.817 
(95% CI: 0.758–0.876) for A1C. Performing an OGTT 
on patients with a FPG $ 5.3 mmol/L or A1C $ 5.8% 
  predicted diabetes with 81% and 83% sensitivity, requiring 
49% and 41% of the patients to be tested, respectively. The 
combined criteria of FPG $ 5.0 mmol/L and A1C $ 5.7% 
provided similar sensitivity (79%) from testing only 29% of 
the population. The authors concluded that OGTT should be 
considered in patients with a FPG between 5.3–6.9 mmol/L or 
glycosylated hemoglobin . 5.8% or in those with combined 
FPG . 5.0 mmol/L and A1C . 5.7%. However, the authors 
acknowledged that 95% of the study population were white 
and the study results might not be valid for patients of other 
ethnicities.
The utility of FPG,   A1C, and OGTT  
in the prediction of NODAT development 
and as a screening tool: summary  
of the literature
A literature review suggests that similar to the general popu-
lation, the 2-hour OGTT diagnostic criteria may be more 
sensitive in identifying patients with IGT or NODAT than 
those set for FPG.
The introduction of A1C as an additional optional diag-
nostic criterion for diabetes mellitus in the general population 
has sparked interest in its use as a screening and diagnostic 
tool in renal transplant recipients. One single-center study 
suggested that A1C level was a more sensitive test than FPG 
in detecting NODAT, particularly in African Americans 
(as discussed in the previous section). However, the major-
ity of patients in the study were African Americans. The 
utility of A1C as the routine screening or diagnostic tool in 
identifying patients with NODAT has yet to be validated in 
patients of other ethnic backgrounds. Clinical studies evalu-
ating the utility of FPG, A1C, and OGTT in the prediction 
of NODAT development and as a screening tool are sum-
marized in Table 2.
Predictive diagnostic tools  
for NODAT development:  
perioperative hyperglycemia  
and diabetes prediction models
New-onset hyperglycemia in the 
immediate postoperative period
Recently, new-onset hyperglycemia in the immediate 
postoperative period (inpatient hyperglycemia) defined 
as bedside capillary glucose of $200 mg/dL on at least 
one measurement, or the administration of insulin therapy 
at any time during the hospital stay, has been suggested 
to be predictive of future NODAT risk.11 Among 377 
primary kidney transplant recipients with at least 1-year 
follow-up, NODAT developed in 4% of patients without 
inpatient hyperglycemia, 18% of patients with inpatient 
hyperglycemia, but not treated with insulin, and in 30% of 
patients who were diagnosed with inpatient hyperglycemia 
and treated with insulin. Further studies are required to 
confirm the utility of new-onset hyperglycemia in the 
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Table 2 Clinical studies evaluating the utility of FPG, A1C, and OGTT in the screening and diagnosis of NODAT
Study protocols Demographic  
characteristics
Study results Conclusions References
FPG and OGTT 
N = 359 
All patients completed  
OGTT 5 days postTx 
Mean follow-up 
42.8 ± 16.9 months
white 91.4% 
Blacks 1.4% 
Arabic 7.2%
•  17.8% developed NODAT 
•    A normal (vs diabetic) OGTT at day 5 postTx  
was associated with ↓NODAT risk  
(OR = 0.03; P = 0.0002) 
Sensitivity, 93.4%; Specificity, 71.9%
•    A normal (vs diabetic) FPG on day 5 postTx  
was associated with ↓NODAT risk  
(OR = 0.06; P , 0.0001) 
Sensitivity, 21.6%; Specificity, 97.6%
A normal FPG  
(vs diabetic) and a  
normal OGTT  
(vs diabetic) at 5 days  
postTx seems to  
identify patients  
at ↓NODAT risk
Kuypers  
et al4
FPG 
N = 282 (patients with  
graft survival . 1 year) 
FPG at day 5 postTx
Spanish study •  16.3% developed NODAT at month 12 
•    A fifth day FPG $126 mg/dL was associated  
with a more than fourfold increase in NODAT  
risk (relative risk: 4.784; P = 0.002)
•    The positive and negative predictive values of a fifth 
day FPG $ 126 mg/dL for predicting NODAT  
at 1-year were 40% and 89.4%, respectively
A negative predictive  
value of 89.4% suggests  
that a FPG , 126 mg/dL  
may identify patients  
with a low risk  
(near 10%) for  
NODAT
Rodrigo  
et al6
FPG and OGTT 
N = 188 . 6 months postTx, 
OGTT performed in patients  
with FPG , 7.0 mmol/L
white . 90% ROC analyses 
•    Optimal FPG predictive of NODAT:  
101 mg/dL; 5.6 mmol/L (AUC = 0.70;  
sensitivity 64%; specificity 67%, positive  
predictive 20%; negative predictive 93%)
•    Optimal FPG predictive of iGT less  
well-defined (AUC = 0.54)
•    Prevalence of NODAT (OGTT vs FPG  
17% vs 6%, respectively; P , 0.0001)
FPG may not be the  
optimal screening or  
diagnostic tool due  
to lack of sensitivity  
and specificity  
OGTT should be  
considered as a routine  
screening test in all renal  
transplant recipients
Armstrong  
et al7
FPG and OGTT 
N = 122 . 6 months postTx 
OGTT performed in patients  
with two FPG values between  
5.6–6.9 mmol/L
white 96% 
Asian 3% 
Afro- 
Caribbean 1%
OGTT revealed 10% had overt DM,  
9% iGT alone, 18% iFG alone,  
14% combined iFG and iGT
FPG underestimates  
iGT and NODAT  
prevalence  
Routine use of OGTT is a  
valuable clinical tool to risk  
stratify patient for NODAT
Sharif  
et al8
FPG and A1C 
N = 199 $3 months postTx 
All patients had a history of  
normal FPG prior to study 
Normal A1C defined  
as ,6.1%
African  
Americans 81.9%
•    Twenty (10.1%) had A1C $ 6.1% (6 of whom  
had both ↑A1C and new onset ↑FPG at study  
entry) and 14 had ↑A1C only
•    Of the 6 patients with both ↑A1C and new  
onset ↑FPG, 5 were diagnosed with NODAT
•    Of the 14 patients with ↑A1C only, 3 were  
diagnosed with NODAT and 4 with  
glucose intolerance
•    The odds of African Americans having ↑A1C  
were 2.8 times higher than other races
•    High normal FPG was significantly associated  
with an ↑A1C (P = 0.003)
•    Race effect marginally significant when adjusted  
for FPG (P = 0.08)
A1C level was a more  
sensitive test than FPG  
in detecting NODAT 
A1C testing should be 
considered as a  
screening test for  
NODAT, especially  
in African Americans
Hoban  
et al9
FPG, A1C, and OGTT 
N = 929 @ 10-week postTx 
Patients who had both  
FPG , 7.0 mmol/L and A1C  
levels available were  
evaluated
white 95% ROC analysis 
•    FPG: AUC 0.761 (95% CI: 0.714–0.809)
•    A1C: AUC 0.817 (95% CI: 0.758–0.876)
•    Performing OGTT on patients with  
FPG $ 5.3 mmol/L or A1C $ 5.8% predicted  
NODAT with 81% and 83% sensitivity, requiring 49% 
and 41% of the patients to be tested, respectively
•    Combined criterion of FPG $ 5.0 mmol/L and  
A1C $ 5.7% provided a sensitivity of 79% from  
testing 29% of the population
OGTT should be  
considered in patients  
with FPG between  
5.3–6.9 mmol/L or  
A1C . 5.8% 
or 
in those with combined  
FPG $ 5 mmol/L and  
A1C $ 5.7%
Valderhaugh  
et al10
Abbreviations: CI, confidence interval; DM, diabetes mellitus; FPG, fasting plasma glucose; OGTT, oral glucose tolerance test; PostTx, posttransplant; ROC, receiver-
operating characteristic; AUC, area under the curve.
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immediate postoperative period in the screening and 
diagnosis of NODAT.
Diabetes prediction models
Prediction of NODAT before kidney transplant
While most studies designed to predict the development of 
NODAT predominantly focus on the assessment of actual 
glucose metabolism, studies in the general population sug-
gested that simple prediction models that incorporate clini-
cal and/or metabolic risk factors (eg, age, family history of 
type 2 diabetes, body mass index [BMI], blood pressure, 
high-density lipoprotein [HDL], triglycerides, and IFG) to 
generate a prediction score may be more effective in predict-
ing diabetes than complex models involving the analysis 
of glucose metabolism such as OGTT, insulin sensitivity, 
and/or insulin resistance. Similar comparative studies in the 
transplant settings are lacking. Nonetheless, studies evaluat-
ing the predictive values of diabetic prone clinical factors 
are emerging.
In one-single center study consisting of 318 nondiabetic 
patients who subsequently received a kidney transplant, 
Chakkera et al12 demonstrated that a simple risk score utiliz-
ing the sum of seven dichotomized pretransplant risk factors 
is comparable with that of a standard multivariate model 
using continuous variables in predicting NODAT (areas 
under the ROC for predicting NODAT were between 0.7 
and 0.72 for all models tested). A score of 0–7 calculated 
from pretransplant age, family history of type 2 diabetes, 
BMI, FPG and triglycerides, use of gout medications, and 
predicted use of posttransplant corticosteroid (nontrans-
plant or immunological indications) were predictive of the 
incidence of NODAT at 1-year posttransplant. The risk of 
NODAT ranged from 13%, for a score of 0 to 1, to 56%, for 
a score of $4 (Table 3). NODAT was defined as having an 
A1C $ 6.5%, FPG $ 126 mg/dL, or the need for dietary 
modification or medical therapy for diabetes between 1 month 
and 1 year posttransplant.
In a different study consisting of 120 nondiabetic 
patients who later received a kidney transplant, Caillard 
et al13 demonstrated that pretransplant IGT, age (more than 
or less than 50 years), and type of nephropathy (presence 
or absence of adult polycystic kidney disease) are helpful 
tools for identifying patients at risk for NODAT. Multivariate 
analysis demonstrated that the risk of developing NODAT 
increased 2.4-fold (0.8–7) in recipients with one risk factor 
(P = 0.1), 5.2-fold (1.8–15) in recipients with two risk fac-
tors (P = 0.02), and 14-fold (3–67) in recipients with three 
risk factors (P = 0.01). The presence of two or three of these 
pretransplant risk factors enabled prediction of NODAT with 
a sensitivity of 48%, specificity of 85%, positive predictive 
value of 55%, and negative predictive value of 83%.
In a retrospective analysis consisting of 640 nondiabetic 
renal transplant recipients, Bayer et al14 demonstrated that 
the prevalence of NODAT at 1 year increased with increas-
ing number of metabolic syndrome score (0, 0%; 1, 24%; 
2, 29%; 3, 31%; 4, 35%; 5, 74%; P = 0.001). Multivariate 
analysis incorporating the individual metabolic syndrome 
components as covariates demonstrated that only low-
density lipoprotein was independently associated with the 
development of NODAT.
Prediction of NODAT after the first  
posttransplant year
In a retrospective study consisting of 191 kidney transplant 
recipients with at least 1-year posttransplant follow-up, 
Rodrigo et al15 showed the Framingham Offspring Study-
Diabetes Mellitus (FOS-DM) and San Antonio Diabetes 
Prediction Model (SADPM) scores that predict type 2 
diabetes mellitus in the general population16,17 can similarly 
predict NODAT in kidney transplant recipients. The SADPM 
includes the variables of age, sex, Mexican-American eth-
nicity, fasting glucose, systolic blood pressure, HDL cho-
lesterol, BMI, and family history of diabetes. The FOS-DM 
model utilizes overweight/obese, impaired fasting glucose, 
HDL cholesterol, hypertriglyceridemia, hypertension, and 
family history of diabetes.18 FOS-DM and SADPM scores 
over the 75 percentile were shown to be associated with a 
five- and eightfold increase in NODAT risk, respectively, 
P , 0.001. The cumulative incidence of NODAT at 6 years 
was significantly higher for patients over the 75 percen-
Table 3 Association of pretransplant risk score with NODAT development
Risk score* (0–7) N (# of patients) 1-year cumulative incidence of NODAT
Low risk (0–1) 109 13%
Intermediate risk (2–3) 170 29%
High risk (4–7) 39 56%
Notes: *A risk score of 0–7 was calculated from seven pretransplant risk factors (age, family history of type 2 diabetes, BMi, FPG, triglycerides, use of gout medications, and 
predicted use of steroids posttransplant).
Abbreviations: BMi, body mass index; FPG, fasting plasma glucose; NODAT, new-onset diabetes after transplantation.
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tile of both FOS-DM (10.7% vs 3.7%; P , 0.001) and 
SADPM scores (11.4% vs 2.1%; P , 0.001). The positive 
and negative predictive values of the FOS-DM score over 
the 75 percentile were 24.5% and 92.5%, respectively. The 
positive and negative predictive values of the SADPM score 
over the 75 percentile were 31.2% and 93.7%, respectively. 
While the low positive predictive values of both scores 
indicate that they cannot be used to identify the future evo-
lution of an individual patient, the high negative predictive 
values of the top quartile suggest that both scores can be 
used to identify the 25% of kidney transplant recipients with 
a higher risk for developing NODAT beyond the first year. 
Notably, the SADPM score detects 25% of kidney transplant 
patients with an eightfold risk for NODAT, suggesting that 
this instrument can be used to define a target population 
for NODAT prevention programs. The authors proposed a 
two-step screening model, using the Chakkera algorithm 
pretransplant11 followed by the SADPM or FOS-DM at 
1 year posttransplant.
Screening strategies and predictive 
diagnostic tools for NODAT 
development: the International 
Consensus Guidelines and the 
authors’ perspectives
The 2003 International Consensus Guidelines recommended 
screening all transplant patients with FPG at least once a week 
for the first 4 weeks, then at 3, 6, and 12 months, and annually 
thereafter. Plasma glucose levels should also be randomly 
monitored at regular intervals, preferably concomitantly with 
immunosuppressant level testing (for patients’ convenience). 
In those with an intermediate FPG, defined as plasma glucose 
between 110–125 mg/dL; 6.1–6.9 mmol/L, and normal FPG, 
defined as FPG , 110 mg/dL; 6.1 mmol/L, a 2-hour OGTT 
should be considered.2
The 2005 updated International Consensus Guidelines 
recommended screening all individuals, regardless of dia-
betic status, with FPG at regular intervals and OGTT be 
performed in those with an intermediate FPG. After the first 
3 months posttransplant, A1C testing should be part of the 
same screening schedule as that of FPG.3
Although the 2-hour OGTT diagnostic criteria may be 
more sensitive in identifying patients with IGT or NODAT 
than those set for FPG, screening all renal transplant patients 
with OGTT may be costly and impractical in clinical practice. 
The 2003 International Consensus Guidelines suggested 
OGTT in patients with intermediate or normal FPG defined as 
FPG , 110 mg/dL (6.1 mmol/L). However, the rationale for 
performing an OGTT in all patients with FPG , 110 mg/dL 
(6.1 mmol/L) was not substantiated and such practice may 
also entail testing a large number of patients, which may 
not be feasible.
In the authors’ opinion, OGTT should be considered in 
patients with multiple risk factors for NODAT, whereas FPG 
or A1C or both can be used to screen or risk stratify patients 
and should be monitored in all renal transplant recipients 
at regular intervals. In the case A1C is used, clinicians 
are advised to confirm that the assays involved have been 
standardized and validated. Additionally, it should be noted 
that A1C cannot be accurately interpreted within the first 
3 months posttransplantation due to various factors including 
possible blood transfusions in the early posttransplant period 
and the presence of anemia or impaired graft function. Blood 
transfusions may render the test invalid while anemia and 
kidney impairment can directly interfere with the A1C assay. 
In islet cell transplant recipients, an artifactual reduction in 
A1C level has been reported in recipients receiving dapsone 
for Pneumocystis carinii (P . jiroveci) prophylaxis.19 The cause 
is unknown but a reduction in red cell lifespan or hemolysis 
or both has been implicated.
The available literature suggests that similar to the 
nontransplant settings, the risk for developing NODAT 
appears to follow a continuum across the entire spectrum of 
subdiabetic glycemic values. Renal transplant recipients with 
higher surveillance FPG, higher A1C levels, or both, may 
convey higher NODAT risk compared with those with lower 
values and are thus justified to undergo OGTT. Whether all 
patients with new-onset hyperglycemia in the immediate 
postoperative period, particularly those requiring insulin, 
should undergo OGTT at long-term follow-up remains to be 
studied. Similarly, whether diabetes prediction models can 
be used to incite further diagnostic testing with an OGTT 
remains to be explored.
Lastly, it should be noted that the International Expert 
Committee has recently advocated the use of standardized 
A1C in the diagnosis of diabetes mellitus in the general 
population. If A1C testing is not possible, FPG or 2-hour 
plasma glucose are considered acceptable alternative diag-
nostic tools.20 In the United States, OGTT has largely been 
abandoned outside of screening for gestational diabetes, 
due to its complexity and low reproducibility.21 However, in 
contrast to the nontransplant settings, the use of A1C in the 
diagnosis of NODAT has not been validated, particularly in 
the early posttransplant period, due to the presence of multiple 
confounding factors. Therefore, OGTT has remained the 
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gold-standard test for the diagnosis of new-onset   diabetes 
after organ transplantation. A suggested algorithm for 
NODAT screening is shown in Figure 1.
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A  Screening frequency
EITHER fasting plasma glucose
•Weeks 1–4: at least weekly
•Weeks 5–8: every 2 weeks 
•Then @ 3, 6, 9, 12 months 
•Then at least annually
AND/OR A1C
• Every 3–6 months (see text)
B  NODAT risk factors
Non-modifiable
• Age > 40–45 years
• African Americans
• Hispanics
• Family history
• Others (see reference 22)
(Potentially) modifiable
• Immunosuppressant choice
• Obesity or other components of 
the metabolic syndrome
• Hepatitis C virus
• Cytomegalovirus
• Others (see reference 22)
C  Definitions: high normal FPG, A1C
• *High normal FPG ≥ 91–99 mg/dL
• *High normal A1C ≥ 5.7%–6.4%
*or at the discretion of the clinician
Normal FPG and/or normal A1C
routine screening (A) 
OGTT
ψ
NODAT
IFG, A1C > 6.4%,
multiple risk factors (B), or
high normal FPG or A1C (C)
Figure 1 Targeting new onset diabetes after transplantation (NODAT).
Note: ψOral Glucose Tolerance Testing (OGTT) is the current gold standard test for the diagnosis of NODAT.
Abbreviations: FPG, fasting plasma glucose; iFG, impaired fasting glucose; NODAT, new-onset diabetes after transplantation.
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